Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
Authors
Keywords
GSK-3 inhibitor, Neuroblastoma, GSK-3 alpha, GSK-3 beta, Apoptosis
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-05-11
DOI
10.1186/s12885-018-4474-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antiproliferative and apoptotic effects of xanthohumol in cholangiocarcinoma
- (2017) Daniel Walden et al. Oncotarget
- Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells
- (2017) Giulia Ferrari-Toninelli et al. NEURO-ONCOLOGY
- Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy
- (2016) Takahiro Domoto et al. CANCER SCIENCE
- Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G 0 /G 1 accumulation and ROS generation
- (2016) Theodore Lemuel Mathuram et al. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
- Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study
- (2015) L L Wang et al. BRITISH JOURNAL OF CANCER
- Role for the PI3K/Akt/Nrf2 signaling pathway in the protective effects of carnosic acid against methylglyoxal-induced neurotoxicity in SH-SY5Y neuroblastoma cells
- (2015) Marcos Roberto de Oliveira et al. CHEMICO-BIOLOGICAL INTERACTIONS
- A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin
- (2015) Jhanelle E. Gray et al. INVESTIGATIONAL NEW DRUGS
- Mesenchymal change and drug resistance in neuroblastoma
- (2015) Jessica A. Naiditch et al. JOURNAL OF SURGICAL RESEARCH
- Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells
- (2015) S. Kunnimalaiyaan et al. MOLECULAR CANCER THERAPEUTICS
- GSK-3 as potential target for therapeutic intervention in cancer
- (2015) James A. McCubrey et al. Oncotarget
- Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth
- (2014) Yvette M Carter et al. CANCER BIOLOGY & THERAPY
- Notch Signaling–related Therapeutic Strategies With Novel Drugs in Neuroblastoma Spheroids
- (2013) Sule Ayla et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
- (2013) D. J. Duffy et al. MOLECULAR CANCER THERAPEUTICS
- Neuroblastoma and MYCN
- (2013) M. Huang et al. Cold Spring Harbor Perspectives in Medicine
- Novel Agents Targeting the IGF-1R/PI3K Pathway Impair Cell Proliferation and Survival in Subsets of Medulloblastoma and Neuroblastoma
- (2012) Anna Wojtalla et al. PLoS One
- Notch pathway activation induces neuroblastoma tumor cell growth arrest
- (2011) Peter E. Zage et al. PEDIATRIC BLOOD & CANCER
- GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line
- (2010) Amy Dickey et al. JOURNAL OF NEURO-ONCOLOGY
- Recent Advances in Neuroblastoma
- (2010) John M. Maris NEW ENGLAND JOURNAL OF MEDICINE
- GSK3β and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells
- (2008) Yuan-Yuan Chen et al. BIOCHEMICAL PHARMACOLOGY
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
- (2008) Susan L. Cohn et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started